XTL Biopharmaceuticals Announces Financial Results for the Year Ended Decembe...(9 General and administrative expenses...),Health

General and administrative expenses

(includes non-cash stock option

compensation of $1,784

and $1,992, in 2007 and 2006,

respectively) 5,582 5,576

Business development costs (includes stock

appreciation rights compensation of

$1,560 in 2007 and also includes

non-cash stock option compensation

of $22 and $15, in 2007

and 2006, respectively) 2,008 641

------------ ------------

Operating loss 25,735 16,046

Financial and other income, net 590 1,141

------------ ------------

Loss before income taxes 25,145 14,905

Income taxes (206) 227

------------ ------------

Loss for the period 24,939 15,132

============ ============

Basic and diluted loss per ordinary share $0.11 $0.08

============ ============

Weighted average number of shares used in

computing basic and diluted loss per

ordinary share 228,492,818 201,737,295

============ ============

Balance Sheet Information:

December 31,

2007 2006*

------------ ------------

(unaudited)

Cash, cash equivalents, and bank

deposits
'/>"/>